 "Alembic Pharma's Aleor Dermaceuticals gets USFDA nod for generic product")
Drug firm Alembic Pharmaceuticals on Wednesday said its joint venture firm Aleor Dermaceuticals has received approval from the US health regulator to market a generic product, which is used to treat various skin conditions, in the American market.
The company said its joint venture firm Aleor has received final approval from the US Food and Drug Administration (USFDA) to market its abbreviated new drug application (ANDA) Clobetasol Propionate Cream in the US market.
The approved product is generic version of Fougera Pharmaceuticals' Temovate Cream which is indicated for relief of inflammatory and pruritic manifestations.
According to IQVIA, the Clobetasol Propionate Cream USP (0.05 per cent) had an estimated market size of USD 57 million (about Rs 405 crore) for the 12-months ending September 2019.
Alembic now has a cumulative total of 118 ANDA approvals from the USFDA.
The company's shares on Wednesday ended 0.41 per cent higher at Rs 634.30 on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app